CONMED (CNMD) Stock Forecast, Price Target & Predictions
CNMD Stock Forecast
CONMED stock forecast is as follows: an average price target of $97.00 (represents a 37.86% upside from CNMD’s last price of $70.36) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CNMD Price Target
The average price target for CONMED (CNMD) is $97.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $97.00 to $97.00. This represents a potential 37.86% upside from CNMD's last price of $70.36.
CNMD Analyst Ratings
According to 3 Wall Street analysts, CONMED's rating consensus is 'Buy'. The analyst rating breakdown for CNMD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CONMED Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 04, 2024 | Mike Matson | Needham | $97.00 | $66.59 | 45.67% | 37.86% |
| Apr 25, 2024 | Matt O\'Brien | Piper Sandler | $95.00 | $64.34 | 47.65% | 35.02% |
| Apr 25, 2024 | Mike Matson | Needham | $107.00 | $70.01 | 52.84% | 52.08% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | $108.00 | $83.39 | 29.51% | 53.50% |
The latest CONMED stock forecast, released on Oct 04, 2024 by Mike Matson from Needham, set a price target of $97.00, which represents a 45.67% increase from the stock price at the time of the forecast ($66.59), and a 37.86% increase from CNMD last price ($70.36).
CONMED Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $97.00 | $99.67 |
| Last Closing Price | $70.36 | $70.36 | $70.36 |
| Upside/Downside | -100.00% | 37.86% | 41.66% |
In the current month, the average price target of CONMED stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CONMED's last price of $70.36. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 04, 2024 | Needham | Buy | Buy | Hold |
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Apr 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 25, 2024 | Needham | Buy | Buy | Hold |
| Feb 01, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Feb 01, 2024 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Needham | Buy | Buy | Hold |
| Apr 27, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 27, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Mar 27, 2023 | KeyBanc | Overweight | Upgrade | |
| Feb 02, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 26, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 14, 2022 | Needham | Buy | Buy | Hold |
CONMED's last stock rating was published by Piper Sandler on Oct 04, 2024. The company gave CNMD a "Underperform" rating, the same as its previous rate.
CONMED Financial Forecast
CONMED Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $327.05M | - | $317.65M | $295.47M | $250.87M | $275.09M | $277.19M | $242.33M | $273.97M | $248.83M | $255.16M | $232.68M | $252.83M | $237.84M |
| Avg Forecast | $432.70M | $402.10M | $420.50M | $393.80M | $395.49M | $366.36M | $384.12M | $359.50M | $365.70M | $340.03M | $356.16M | $334.73M | $340.96M | $317.78M | $334.39M | $306.75M | $332.21M | $301.42M | $306.15M | $266.63M | $302.48M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| High Forecast | $436.91M | $406.01M | $424.59M | $397.63M | $399.33M | $369.93M | $387.86M | $362.99M | $369.26M | $343.34M | $359.62M | $338.62M | $342.37M | $318.26M | $334.39M | $306.75M | $335.16M | $303.70M | $309.13M | $269.22M | $305.42M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| Low Forecast | $427.58M | $397.34M | $415.52M | $389.14M | $390.80M | $362.03M | $379.57M | $355.24M | $361.37M | $336.00M | $351.94M | $329.71M | $338.69M | $317.31M | $334.39M | $306.75M | $331.27M | $297.71M | $302.53M | $263.48M | $298.90M | $280.83M | $275.75M | $235.77M | $275.82M | $255.23M | $248.47M | $216.77M | $262.90M | $205.92M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | - | 1.04% | 1.11% | 0.83% | 0.98% | 1.01% | 1.03% | 0.99% | 0.97% | 1.03% | 1.07% | 0.96% | 1.15% |
CONMED's average Quarter revenue forecast for Mar 24 based on 3 analysts is $306.75M, with a low forecast of $306.75M, and a high forecast of $306.75M. CNMD's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $327.05M (Dec 23).
CONMED EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $60.97M | - | $27.42M | $12.70M | $-1.09M | $24.25M | $-87.55M | $22.44M | $54.69M | $42.79M | $43.49M | $38.36M | $42.65M | $47.26M |
| Avg Forecast | $50.30M | $46.75M | $48.89M | $45.78M | $45.98M | $42.59M | $44.66M | $41.79M | $42.52M | $39.53M | $41.41M | $38.91M | $39.64M | $36.94M | $38.88M | $47.60M | $38.62M | $35.04M | $35.59M | $43.27M | $57.83M | $19.35M | $19.00M | $34.21M | $19.00M | $17.58M | $17.12M | $23.97M | $18.11M | $14.19M |
| High Forecast | $50.79M | $47.20M | $49.36M | $46.23M | $46.43M | $43.01M | $45.09M | $42.20M | $42.93M | $39.92M | $41.81M | $39.37M | $39.80M | $37.00M | $38.88M | $57.12M | $38.97M | $35.31M | $35.94M | $51.93M | $69.39M | $19.35M | $19.00M | $41.05M | $19.00M | $17.58M | $17.12M | $28.77M | $18.11M | $14.19M |
| Low Forecast | $49.71M | $46.19M | $48.31M | $45.24M | $45.43M | $42.09M | $44.13M | $41.30M | $42.01M | $39.06M | $40.92M | $38.33M | $39.38M | $36.89M | $38.88M | $38.08M | $38.51M | $34.61M | $35.17M | $34.62M | $46.26M | $19.35M | $19.00M | $27.37M | $19.00M | $17.58M | $17.12M | $19.18M | $18.11M | $14.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.58% | - | 0.77% | 0.29% | -0.02% | 1.25% | -4.61% | 0.66% | 2.88% | 2.43% | 2.54% | 1.60% | 2.35% | 3.33% |
3 analysts predict CNMD's average Quarter EBITDA for Mar 24 to be $47.60M, with a high of $57.12M and a low of $38.08M. This is -21.93% lower than CONMED's previous annual EBITDA (Dec 23) of $60.97M.
CONMED Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $33.07M | - | $13.73M | $1.82M | $26.58M | $46.15M | $-168.29M | $14.97M | $24.44M | $14.95M | $13.29M | $9.86M | $24.14M | $6.85M |
| Avg Forecast | - | - | - | - | $52.09M | $42.98M | $42.91M | $36.04M | $42.33M | $36.47M | $37.18M | $32.10M | $37.49M | $31.83M | $28.31M | $18.15M | $34.57M | $26.10M | $24.70M | $16.50M | $25.84M | $23.39M | $23.47M | $13.04M | $31.99M | $23.32M | $19.24M | $6.16M | $23.81M | $7.10M |
| High Forecast | - | - | - | - | $52.75M | $43.52M | $43.46M | $36.50M | $42.86M | $36.93M | $37.65M | $38.14M | $37.96M | $32.36M | $28.31M | $21.78M | $34.88M | $26.41M | $25.01M | $19.80M | $31.01M | $23.39M | $23.47M | $15.65M | $31.99M | $23.32M | $19.24M | $7.39M | $23.81M | $7.10M |
| Low Forecast | - | - | - | - | $51.29M | $42.31M | $42.25M | $35.49M | $41.67M | $35.91M | $36.61M | $28.29M | $36.91M | $31.30M | $28.31M | $14.52M | $34.26M | $25.78M | $24.32M | $13.20M | $20.68M | $23.39M | $23.47M | $10.43M | $31.99M | $23.32M | $19.24M | $4.93M | $23.81M | $7.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | - | 0.56% | 0.11% | 1.03% | 1.97% | -7.17% | 1.15% | 0.76% | 0.64% | 0.69% | 1.60% | 1.01% | 0.96% |
CONMED's average Quarter net income forecast for Mar 24 is $18.15M, with a range of $14.52M to $21.78M. CNMD's average Quarter net income forecast represents a -45.12% decrease compared to the company's last Quarter net income of $33.07M (Dec 23).
CONMED SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $127.33M | - | $129.70M | $130.08M | $120.74M | $114.60M | $115.83M | $102.88M | $107.28M | $104.74M | $104.40M | $98.34M | $99.10M | $94.38M |
| Avg Forecast | $181.95M | $169.09M | $176.82M | $165.60M | $166.30M | $154.06M | $161.53M | $151.17M | $153.78M | $142.98M | $149.77M | $140.76M | $143.38M | $133.63M | $140.61M | $124.68M | $139.70M | $126.75M | $128.74M | $113.35M | $113.42M | $116.12M | $114.02M | $89.60M | $114.05M | $105.54M | $102.74M | $61.46M | $108.71M | $85.15M |
| High Forecast | $183.72M | $170.73M | $178.54M | $167.21M | $167.92M | $155.56M | $163.10M | $152.64M | $155.28M | $144.37M | $151.22M | $142.39M | $143.97M | $133.83M | $140.61M | $149.62M | $140.94M | $127.71M | $129.99M | $136.01M | $136.11M | $116.12M | $114.02M | $107.52M | $114.05M | $105.54M | $102.74M | $73.75M | $108.71M | $85.15M |
| Low Forecast | $179.80M | $167.08M | $174.73M | $163.64M | $164.34M | $152.23M | $159.61M | $149.38M | $151.96M | $141.29M | $147.99M | $138.64M | $142.42M | $133.43M | $140.61M | $99.74M | $139.30M | $125.19M | $127.22M | $90.68M | $90.74M | $116.12M | $114.02M | $71.68M | $114.05M | $105.54M | $102.74M | $49.17M | $108.71M | $85.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | - | 1.01% | 1.15% | 1.06% | 0.99% | 1.02% | 1.15% | 0.94% | 0.99% | 1.02% | 1.60% | 0.91% | 1.11% |
CONMED's average Quarter SG&A projection for Mar 24 is $124.68M, based on 3 Wall Street analysts, with a range of $99.74M to $149.62M. The forecast indicates a -2.08% fall compared to CNMD last annual SG&A of $127.33M (Dec 23).
CONMED EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.05 | - | $0.45 | $0.06 | $0.87 | $1.51 | $-5.65 | $0.51 | $0.83 | $0.51 | $0.46 | $0.34 | $0.84 | $0.24 |
| Avg Forecast | - | - | - | - | $1.67 | $1.38 | $1.38 | $1.16 | $1.36 | $1.17 | $1.20 | $1.03 | $1.21 | $1.02 | $0.91 | $0.74 | $1.11 | $0.84 | $0.79 | $0.60 | $0.90 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| High Forecast | - | - | - | - | $1.70 | $1.40 | $1.40 | $1.17 | $1.38 | $1.19 | $1.21 | $1.23 | $1.22 | $1.04 | $0.91 | $0.74 | $1.12 | $0.85 | $0.80 | $0.61 | $0.92 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| Low Forecast | - | - | - | - | $1.65 | $1.36 | $1.36 | $1.14 | $1.34 | $1.15 | $1.18 | $0.91 | $1.19 | $1.01 | $0.91 | $0.74 | $1.10 | $0.83 | $0.78 | $0.59 | $0.89 | $0.75 | $0.75 | $0.62 | $1.03 | $0.75 | $0.62 | $0.44 | $0.77 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | - | 0.57% | 0.10% | 0.96% | 2.01% | -7.49% | 0.82% | 0.81% | 0.68% | 0.74% | 0.78% | 1.10% | 1.05% |
According to 3 Wall Street analysts, CONMED's projected average Quarter EPS for Mar 24 is $0.74, with a low estimate of $0.74 and a high estimate of $0.74. This represents a -29.73% decrease compared to CNMD previous annual EPS of $1.05 (Dec 23).
CONMED Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SGHT | Sight Sciences | $3.55 | $7.50 | 111.27% | Hold |
| LUNG | Pulmonx | $6.16 | $13.00 | 111.04% | Buy |
| ATEC | Alphatec | $9.23 | $16.60 | 79.85% | Buy |
| KIDS | OrthoPediatrics | $22.58 | $39.50 | 74.93% | Buy |
| LIVN | LivaNova | $46.75 | $68.25 | 45.99% | Buy |
| SIBN | SI-BONE | $13.27 | $18.50 | 39.41% | Buy |
| CNMD | CONMED | $69.91 | $97.00 | 38.75% | Buy |
| OFIX | Orthofix Medical | $17.34 | $24.00 | 38.41% | |
| STE | STERIS | $208.79 | $262.50 | 25.72% | Buy |
| IRTC | iRhythm | $89.37 | $110.86 | 24.05% | Buy |
| ITGR | Integer | $134.75 | $153.50 | 13.91% | Buy |
| GMED | Globus Medical | $83.47 | $85.00 | 1.83% | Buy |
| SRDX | Surmodics | $39.68 | $39.50 | -0.45% | Buy |
| GKOS | Glaukos | $151.22 | $148.86 | -1.56% | Buy |